


SARS-CoV-2 Sequencing Update **05 August 2022**



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

Department

Science and Innovation

REPUBLIC OF SOUTH AFRICA

The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 04 August 2022 at 09h11




Data license: https://www.gisaid.org/registration/terms-of-use/


Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101

Number of South African genomes deposited on GISAID, by specimen collection week, 2020 – 2022 (N=44 148*)




GISAID genomes vs total cases, 2020 – 2022 (N=44 148)






Number and percentage of clades by epiweek in South Africa, 2021 – 2022 (37 324*)




epiweeks in 2021 - 2022



NGS-SA Network for Genomic Surveillance in South Africa


Detection Rates: Beta, Delta, C.1.2 and Omicron

Detection rates of variants being monitored in South Africa



Surveillance in South Africa


South Africa, 2021-2022, n = 37 324*



*Excludes sequences missing collection dates, as well as those collected January 1st and 2nd 2021 as they are part of epiweek 53 of 2020.

Eastern Cape Province, 2021-2022, n = 2956


Genomes added since last report: 54*



Surveillance in South Africa

Free State Province, 2021-2022, n = 1582


Genomes added since last report: 7*



Surveillance in South Africa

Gauteng Province, 2021-2022, n = 10 417


Genomes added since last report: 125*



Surveillance in South Africa


KwaZulu-Natal Province, 2021-2022, n = 4116

Genomes added since last report: 36*




Limpopo Province, 2021-2022, n = 2599

Genomes added since last report: 25*




Mpumalanga Province, 2021-2022, n = 2814

Genomes added since last report: 110*




Northern Cape Province, 2021-2022, n = 1843

Genomes added since last report: 2*




North West Province, 2021-2022, n = 2217

Genomes added since last report: 36*



Western Cape Province, 2021-2022, n = 8771

Genomes added since last report: 0*



Surveillance in South Africa

Summary

Sequencing update

- All provinces have contributed sequences for April, May, and June. July sequences are from all provinces except LP and NC.
- Omicron dominated in May (99.5%), June (98.5%) and July (98.9%). BA.4 and BA.5 together were dominant in May, June and July.

• N=9 sequences with novel mutational profile


- One additional sequence has been detected (collection date 18th July 2022)
- No recent sequences have been detected but NGS-SA teams are closely monitoring the data

• Variant of Concern Omicron in South Africa

- Dominates 2022 sequencing data at >98% of genomes.
- While BA.1 was the predominant lineage in January (55%), BA.2 dominated in February (86%) and March (78%).
- Omicron lineages BA.4 and BA.5 increased in prevalence in March (16%), and together are dominant in April (73%), May (93%), June (92%) and July (94%).
- BA.2.12.1 was detected in South Africa at low prevalence in May, June and July (<1%)
- Low frequency of previously circulating variants such as Delta still detected in recent data.



Spike protein mutation* profile of Variants of Interest and Concern




Spike mutations

- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
 - Including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
 - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape

*Only mutations present in Omicron, Delta, or the new SGTP sequences are pictured



BA.4 and BA.5 spike mutations



Frequency of spike SNVs for Omicron (22A/BA.4.*) (n = 3582)

NTD RBD RBM S1 S2 HR1

Mutation





NATIONAL HEALTH LABORATORY SERVICE

XX

ЕDСТР

University of Stellenbosch & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga **Bronwyn Kleinhans** Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen **Diagnostic laboratory staff**

UKZN-Inkosi Albert Luthuli Central Hospital



Dr Khanvi Msomi Dr Neli Ngcaba Dr Kerusha Govender Dr Tshepiso Mosito Dr Pravi Moodley Mr Malcolm Ellapen Dr Aabida Khan Mr Kubendran Reddy Dr Lili Gounder The COVID-19 Bench team Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty

University of KwaZulu-Natal & Africa **Health Research Institute**



Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San**

KRISP at UKZN:

AHRI **AHRT**AFRICA RESEARCH INSTITUTE Alex Sigal Sandile Cele Willem Hanekom

University of the



Free State

UFS

Dominique Goedhals Armand Bester Martin Myaga Peter Mwangi Emmanuel Ogunbayo Milton Mogotsi Makgotso Maotoana Lutfiyya Mohamed



NHLS Division of Virology Sabeehah Vawda Felicity Burt Thokozani Mkhize **Diagnostic laboratory staff**



University of Cape Town, NHLS & Western Cape Government health

101046041

AA

EDCTP

ABONATIONAL HEALT NHLS-UCT

Nei-yuan Hsiao

Diana Hardie

Kruger Marais

Ziyaad Valley-Omar

WCG-UCT Mary-Anne Davies Carolyn Williamson Hannah Hussev Andrew Boulle Masudah Paleker Theuns Jacobs Stephen Korsman

Department. Health REPUBLIC OF SOUTH ATRICA



UCT. IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Wendy Burgers Nokuzola Mbhele Ntobeko Ntusi Fezokuhle Khumalo Rageema Joseph Thabang Serakge Sean Wasserman Bruna Galvão Linda Boloko Arghavan Alisoltani (U. California)

NHLS Greenpoint Annabel Enoch This project has ceived funding from he European Union's Horizon Europe Ì Research and Erna Morden Innovation Actions under grant No.



W Robert Wilkinson Darren Martin Nicola Mulder

centre infectious (



CAPE TOWN HVTN

cience & innovation etrent: nos and knovation VELIC OF SOUTH AFRICA

Zoonotic arbo and respiratory virus program **Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria**

> ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist) Carien van Niekerk

NHLS Tshwane

Prof Simnikiwe Mayaphi (HOD)

Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

National Institute for Communicable Diseases

Jinal Bhiman

Cathrine Scheepers

Thandeka Movo

Frances Ayres

Zanele Molaudzi

Bronwen Lambson

Tandile Hermanus

Prudence Kgagudi

Brent Oosthuysen

AFRICA CDC

Mashudu Madzivhandila

Tandile Hermanus



Centre for Respiratory Diseases & Meningitis Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter Sibongile Walaza Mignon du Plessis

Stefano Tempia Mvuyo Makhasi **Cheryl Cohen**



Centre for HIV and STIs Sequencing Core Facility Zamantungwa Khumalo Annie Chan **Constantinos Kurt Wibmer** Morne du Plessis Stanford Kwenda **Mushal Allam**

Phillip Senzo Mtshali Florah Mnyameni Arshad Ismail











Penny Moore Lynn Morris

NICD Groups NICD COVID-19 response team NICD SARS-CoV-2 Sequencing Group





Key to Diagnostic Excellent

ΑΜΡΑΤΗ

LABORATORIES

PathCare

1

Vermaak

africa

aboratorie

FIOCRUZ

NHLS Koeleka Mlisana Zinhle Makatini Eugene Elliot Florette K. Treurnicht Kathleen Subramoney Oluwakemi Laguda-Akingba Shareef Abrahams Greta Hoyland Gloria Selabe

Jeannette Wadula

Elias Bereda

Hyrax Biosciences Simon Travers

Cape Town HVTN Laboratory Erica Anderson-Nissen Anneta Naidoo

Ndlovu Research Hugo Tempelman CJ Umunnakwe **Lancet** Allison J. Glass Raquel Viana

Ampath Terry Marshall Cindy van Deventer Eddie Silberbauer

Pathcare Vermaak Andries Dreyer Howard Newman Riaan Writes Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

Cytespace Africa Laboratories Christa Viljoen

ARC-OVI Lia Rotherham **CAPRISA** Salim Abdool Karim Nigel Garret

Additional support and collaborators

UKZN - Big Data Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara **Africa CDC** John Nkengasong Sofonias Tessema

Netcare: Richard Friedland Craig Murphy Caroline Maslo Liza Sitharam

DSI

Glaudina Loots

SA MRC Glenda Gray


















South African genomes submitted per submitting lab, 2020 - 2022 (N=44 148)



Submitting labs in South Africa

NGS-SA Labs

CERI: Centre for Epidemic Response and Innovation KRISP: KZN Research Innovation and Sequencing Platform NDLOVU: Ndlovu Research Laboratories NICD: National Institute for Communicable Diseases NHLS: National Health Laboratory Service SU: Stellenbosch University UCT: University of Cape Town UFS: University of the Free State UP: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



Currently circulating Variants of Concern (VOC)

| WHO label | Pango lineage∙ | GISAID clade | Nextstrain clade | Additional amino acid changes monitored° | Earliest documented samples | Date of designation |
|-----------|-------------------|--------------|------------------|---|------------------------------------|--------------------------------------|
| Delta | B.1.617.2 | G/478K.V1 | 21A, 21I, 21J | +S:K417N +S:K484K | India, Oct-2020 | VOI: 4-Apr-2021 VOC: 11-May-2021 |
| Omicron* | B.1.1.529 | GR/484A | 21K | +S:R346K | Multiple countries, Nov-2021 | VUM: 24-Nov-2021 VOC: 26-Nov-2021 |

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 18 March 2022

•Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

• Only found in a subset of sequences

Previously circulating Variants of Concern

| WHO label | Pango lineage● | GISAID clade | Nextstrain clade | Earliest documented samples | Date of designation |
|-----------|-------------------|--------------|------------------|-----------------------------------|---|
| Alpha | B.1.1.7 | GRY | 20I (V1) | United Kingdom, Sep-2020 | VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022 |
| Beta | B.1.351 | GH/501Y.V2 | 20H (V2) | South Africa, May-2020 | VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022 |
| Gamma | P.1 | GR/501Y.V3 | 20J (V3) | Brazil, Nov-2020 | VOC: 11-Jan-2021 Previous VOC: 09-Mar-2022 |

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 18 March 2022

• Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)